Literature DB >> 33352233

PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats.

Majken B Thomsen1, Sara A Ferreira2, Anna C Schacht3, Jan Jacobsen3, Mette Simonsen3, Cristine Betzer2, Poul H Jensen2, David J Brooks4, Anne M Landau5, Marina Romero-Ramos6.   

Abstract

Alpha-synuclein (a-syn) can aggregate and form toxic oligomers and insoluble fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a major pathological characteristic of Parkinson's disease (PD). These fibrillar structures can act as seeds and accelerate the aggregation of monomeric a-syn. Indeed, recent studies show that injection of preformed a-syn fibrils (PFF) into the rodent brain can induce aggregation of the endogenous monomeric a-syn resulting in neuronal dysfunction and eventual cell death. We injected 8 μg of murine a-syn PFF, or soluble monomeric a-syn into the right striatum of rats. The animals were monitored behaviourally using the cylinder test, which measures paw asymmetry, and the corridor task that measures lateralized sensorimotor response to sugar treats. In vivo PET imaging was performed after 6, 13 and 22 weeks using [11C]DTBZ, a marker of the vesicular monoamine 2 transporter (VMAT2), and after 15 and 22 weeks using [11C]UCB-J, a marker of synaptic SV2A protein in nerve terminals. Histology was performed at the three time points using antibodies against dopaminergic markers, aggregated a-syn, and MHCII to evaluate the immune response. While the a-syn PFF injection caused only mild behavioural changes, [11C]DTBZ PET showed a significant and progressive decrease of VMAT2 binding in the ipsilateral striatum. This was accompanied by a small progressive decrease in [11C]UCB-J binding in the same area. In addition, our histological analysis revealed a gradual spread of misfolded a-syn pathology in areas anatomically connected to striatum that became bilateral with time. The striatal a-syn PFF injection resulted in a progressive unilateral degeneration of dopamine terminals, and an early and sustained presence of MHCII positive ramified microglia in the ipsilateral striatum and substantia nigra. Our study shows that striatal injections of a-syn fibrils induce progressive pathological synaptic dysfunction prior to cell death that can be detected in vivo with PET. We confirm that intrastriatal injection of a-syn PFFs provides a model of progressive a-syn pathology with loss of dopaminergic and synaptic function accompanied by neuroinflammation, as found in human PD.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DTBZ; PET; Parkinson; Preformed fibrils; UCB-J; a-synuclein

Year:  2020        PMID: 33352233     DOI: 10.1016/j.nbd.2020.105229

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  9 in total

1.  Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance.

Authors:  Huili Cui; Wenkang Wang; Xinhui Zheng; Danhao Xia; Han Liu; Chi Qin; Haiyan Tian; Junfang Teng
Journal:  J Mol Neurosci       Date:  2021-03-26       Impact factor: 3.444

2.  The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.

Authors:  Vishakh Iyer; Kala Venkiteswaran; Sandip Savaliya; Christopher A Lieu; Erin Handly; Timothy P Gilmour; Allen R Kunselman; Thyagarajan Subramanian
Journal:  Neurobiol Dis       Date:  2021-08-27       Impact factor: 5.996

Review 3.  Synaptic Vesicle Glycoprotein 2A: Features and Functions.

Authors:  Rachele Rossi; Shokouh Arjmand; Simone Larsen Bærentzen; Albert Gjedde; Anne M Landau
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 5.152

4.  Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential.

Authors:  Nelson Ferreira; Hjalte Gram; Zachary A Sorrentino; Emil Gregersen; Sissel Ida Schmidt; Lasse Reimer; Cristine Betzer; Clara Perez-Gozalbo; Marjo Beltoja; Madhu Nagaraj; Jie Wang; Jan S Nowak; Mingdong Dong; Katarina Willén; Ersoy Cholak; Kaare Bjerregaard-Andersen; Nicolas Mendez; Prakruti Rabadia; Mohammad Shahnawaz; Claudio Soto; Daniel E Otzen; Ümit Akbey; Morten Meyer; Benoit I Giasson; Marina Romero-Ramos; Poul Henning Jensen
Journal:  Acta Neuropathol       Date:  2021-05-12       Impact factor: 17.088

5.  Schwann cells differentiated from skin-derived precursors provide neuroprotection via autophagy inhibition in a cellular model of Parkinson's disease.

Authors:  Jia-Nan Yan; Hai-Ying Zhang; Jun-Rui Li; Ying Chen; Yong-Cheng Jiang; Jia-Bing Shen; Kai-Fu Ke; Xiao-Su Gu
Journal:  Neural Regen Res       Date:  2022-06       Impact factor: 5.135

Review 6.  A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model.

Authors:  Nicole K Polinski
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

7.  Dopaminergic Positron Emission Tomography Imaging in the Alpha-Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease.

Authors:  Vesna Sossi; Joseph R Patterson; Siobhan McCormick; Christopher J Kemp; Kathryn M Miller; Anna C Stoll; Nathan Kuhn; Michael Kubik; Joseph Kochmanski; Kelvin C Luk; Caryl E Sortwell
Journal:  Mov Disord       Date:  2022-05-07       Impact factor: 9.698

Review 8.  Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.

Authors:  Yunna Li; Yun Xia; Sijia Yin; Fang Wan; Junjie Hu; Liang Kou; Yadi Sun; Jiawei Wu; Qiulu Zhou; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Front Immunol       Date:  2021-10-08       Impact factor: 7.561

9.  α-Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease.

Authors:  Kathrine Stokholm; Majken Borup Thomsen; Jenny-Ann Phan; Line K Møller; Cecilie Bay-Richter; Søren H Christiansen; David P D Woldbye; Marina Romero-Ramos; Anne M Landau
Journal:  Biomedicines       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.